Testosterone and colorectal cancer: a bidirectional Mendelian randomization study.

IF 1.5 4区医学 Q4 ONCOLOGY

Translational cancer research Pub Date : 2025-01-31 Epub Date: 2025-01-17 DOI:10.21037/tcr-24-1481

Junxing Li, Xinmei Yan, Huyu Jiao, Jingjing Chen, Zhengang Zhang

{"title":"Testosterone and colorectal cancer: a bidirectional Mendelian randomization study.","authors":"Junxing Li, Xinmei Yan, Huyu Jiao, Jingjing Chen, Zhengang Zhang","doi":"10.21037/tcr-24-1481","DOIUrl":null,"url":null,"abstract":"Background: Although Mendelian randomization (MR) studies have been conducted on the causal relationship of testosterone on colorectal cancer (CRC), the result remains controversial. We aimed to explore the genetically determined relationships between total testosterone (TT) and bioavailable testosterone (BT) with CRC using a larger sample size and more stringent methods to exclude confounding factors.Methods: Based on genome wide association studies (GWAS) data of TT, BT and CRC, we utilized bidirectional two-sample MR methods to analyze their interrelationships. Causal relationship analysis was conducted using inverse variance weighting (IVW), MR-Egger, weighted median, simple mode and weighted mode. Sensitivity analyses were performed to examine the stability of the causal relationships.Results: The bidirectional MR analysis revealed one standard deviation (SD) increase in genetically predicted BT increased the risk of CRC [IVW: odds ratio (OR) =1.834, 95% confidence interval (CI): 1.121-3.001, P=0.02] and there was no causal relationship of CRC on BT. There was no causal relationship between CRC and TT.Conclusions: The findings of this study revealed a causal effect of BT on the risk of CRC, and CRC may not affect BT levels. Additionally, there was no causal relationship found between CRC and TT. Our results enhance the understanding of the real causal relationship between testosterone and CRC.","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 1","pages":"71-77"},"PeriodicalIF":1.5000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833406/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-1481","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/17 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Although Mendelian randomization (MR) studies have been conducted on the causal relationship of testosterone on colorectal cancer (CRC), the result remains controversial. We aimed to explore the genetically determined relationships between total testosterone (TT) and bioavailable testosterone (BT) with CRC using a larger sample size and more stringent methods to exclude confounding factors.

Methods: Based on genome wide association studies (GWAS) data of TT, BT and CRC, we utilized bidirectional two-sample MR methods to analyze their interrelationships. Causal relationship analysis was conducted using inverse variance weighting (IVW), MR-Egger, weighted median, simple mode and weighted mode. Sensitivity analyses were performed to examine the stability of the causal relationships.

Results: The bidirectional MR analysis revealed one standard deviation (SD) increase in genetically predicted BT increased the risk of CRC [IVW: odds ratio (OR) =1.834, 95% confidence interval (CI): 1.121-3.001, P=0.02] and there was no causal relationship of CRC on BT. There was no causal relationship between CRC and TT.

Conclusions: The findings of this study revealed a causal effect of BT on the risk of CRC, and CRC may not affect BT levels. Additionally, there was no causal relationship found between CRC and TT. Our results enhance the understanding of the real causal relationship between testosterone and CRC.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational cancer research ONCOLOGY-

CiteScore

2.10

自引率

0.00%

发文量

252

期刊介绍： Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.